Accumulating Evidence for the Association and Shared Pathogenic Mechanisms Between Psoriasis and Cardiovascular-related Comorbidities


      The International Psoriasis Council, a global nonprofit organization dedicated to advancing psoriasis research and treatment, led an initiative to better define the association of various cardiometabolic comorbidities with psoriasis. In November 2013, a workshop was held in Boston, Mass. By assembling a panel of global dermatology, immunology, and cardiovascular experts, the objective was to better define the current status of the science that explains the association of psoriasis with various cardiometabolic-related comorbidities. The International Psoriasis Council has played a historical role in associating psoriasis with various comorbidities by integrating multidisciplinary expertise to advance the scientific and clinical knowledge through publications and clinical trials. This report synthesizes the current understanding of psoriasis with various cardiometabolic risk factors by exploring the potential shared pathogenic mechanisms and genetic connectivity.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Armstrong A.W.
        • Harskamp C.T.
        • Armstrong E.J.
        Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis.
        JAMA Dermatol. 2013; 149: 84-91
        • Wan J.
        • Wang S.
        • Haynes K.
        • Denburg M.R.
        • Shin D.B.
        • Gelfand J.M.
        Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study.
        BMJ. 2013; 347: f5961
        • Wu J.J.
        • Poon K.Y.
        • Channual J.C.
        • Shen A.Y.
        Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.
        Arch Dermatol. 2012; 148: 1244-1250
        • Ahlehoff O.
        • Skov L.
        • Gislason G.
        • et al.
        Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study.
        J Intern Med. 2013; 273: 197-204
        • Mehta N.N.
        • Li K.
        • Szapary P.
        • Krueger J.
        • Brodmerkel C.
        Modulation of cardiometabolic pathways in skin and serum from patients with psoriasis.
        J Transl Med. 2013; 11: 194
        • Suarez-Farinas M.
        • Li K.
        • Fuentes-Duculan J.
        • Hayden K.
        • Brodmerkel C.
        • Krueger J.G.
        Expanding the psoriasis disease profile: Interrogation of the skin and serum of patients with moderate-to-severe psoriasis.
        J Invest Dermatol. 2012; 132: 2552-2564
        • Tian S.
        • Krueger J.G.
        • Li K.
        • et al.
        Meta-analysis derived (MAD) transcriptome of psoriasis defines the “core” pathogenesis of disease.
        PLoS One. 2012; 7: e44274
        • Butcher M.
        • Galkina E.
        Current views on the functions of interleukin-17A-producing cells in atherosclerosis.
        Thromb Haemost. 2011; 106: 787-795
        • Gelfand J.M.
        • Neimann A.L.
        • Shin D.B.
        • Wang X.
        • Margolis D.J.
        • Troxel A.B.
        Risk of myocardial infarction in patients with psoriasis.
        JAMA. 2006; 296: 1735-1741
        • Gelfand J.M.
        • Dommasch E.D.
        • Shin D.B.
        • et al.
        The risk of stroke in patients with psoriasis.
        J Invest Dermatol. 2009; 129: 2411-2418
        • Henseler T.
        • Christophers E.
        Disease concomitance in psoriasis.
        J Am Acad Dermatol. 1995; 32: 982-986
        • Gupta Y.
        • Moller S.
        • Zillikens D.
        • Boehncke W.H.
        • Ibrahim S.M.
        • Ludwig R.J.
        Genetic control of psoriasis is relatively distinct from that of metabolic syndrome and coronary artery disease.
        Exp Dermatol. 2013; 22: 552-553
        • Wang Y.
        • Gao H.
        • Loyd C.M.
        • et al.
        Chronic skin-specific inflammation promotes vascular inflammation and thrombosis.
        J Invest Dermatol. 2012; 132: 2067-2075
        • Mehta N.N.
        • Yu Y.
        • Saboury B.
        • et al.
        Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study.
        Arch Dermatol. 2011; 147: 1031-1039
        • Davidovici B.B.
        • Sattar N.
        • Prinz J.
        • et al.
        Psoriasis and systemic inflammatory diseases: Potential mechanistic links between skin disease and co-morbid conditions.
        J Invest Dermatol. 2010; 130: 1785-1796
        • Alexandroff A.B.
        • Pauriah M.
        • Camp R.D.
        • Lang C.C.
        • Struthers A.D.
        • Armstrong D.J.
        More than skin deep: atherosclerosis as a systemic manifestation of psoriasis.
        Br J Dermatol. 2009; 161: 1-7
        • Nair R.P.
        • Ruether A.
        • Stuart P.E.
        • et al.
        Polymorphisms of the IL12B and IL23R genes are associated with psoriasis.
        J Invest Dermatol. 2008; 128: 1653-1661
        • Mehta N.N.
        • McGillicuddy F.C.
        • Anderson P.D.
        • et al.
        Experimental endotoxemia induces adipose inflammation and insulin resistance in humans.
        Diabetes. 2010; 59: 172-181
        • Shah R.
        • Hinkle C.C.
        • Haris L.
        • et al.
        Adipose genes down-regulated during experimental endotoxemia are also suppressed in obesity.
        J Clin Endocrinol Metab. 2012; 97: E2152-E2159
        • Mehta N.N.
        • Heffron S.P.
        • Patel P.N.
        • et al.
        A human model of inflammatory cardio-metabolic dysfunction; a double blind placebo-controlled crossover trial.
        J Transl Med. 2012; 10: 124
        • Basu S.
        • Zaidi H.
        • Houseni M.
        • et al.
        Novel quantitative techniques for assessing regional and global function and structure based on modern imaging modalities: Implications for normal variation, aging and diseased states.
        Semin Nucl Med. 2007; 37: 223-239
        • Bural G.G.
        • Torigian D.A.
        • Botvinick E.
        • et al.
        A pilot study of changes in (18)F-FDG uptake, calcification and global metabolic activity of the aorta with aging.
        Hell J Nucl Med. 2009; 12: 123-128
        • Tahara N.
        • Kai H.
        • Ishibashi M.
        • et al.
        Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography.
        J Am Coll Cardiol. 2006; 48: 1825-1831
        • Paulmier B.
        • Duet M.
        • Khayat R.
        • et al.
        Arterial wall uptake of fluorodeoxyglucose on PET imaging in stable cancer disease patients indicates higher risk for cardiovascular events.
        J Nucl Cardiol. 2008; 15: 209-217
        • Rominger A.
        • Saam T.
        • Wolpers S.
        • et al.
        18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease.
        J Nucl Med. 2009; 50: 1611-1620
        • Dave J.
        • Ahlman M.A.
        • Lockshin B.N.
        • Bluemke D.A.
        • Mehta N.N.
        Vascular inflammation in psoriasis localizes to the arterial wall using a novel imaging technique.
        J Am Acad Dermatol. 2014; 70: 1137-1138
        • Chen R.
        • Mias G.I.
        • Li-Pook-Than J.
        • et al.
        Personal omics profiling reveals dynamic molecular and medical phenotypes.
        Cell. 2012; 148: 1293-1307
        • Stone N.J.
        • Robinson J.G.
        • Lichtenstein A.H.
        • et al.
        Treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: synopsis of the 2013 ACC/AHA cholesterol guideline.
        Ann Intern Med. 2014; 160: 339-343